SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna^® vaccinated patients on maintenance immunoapheresis - a cohort study.

ABSTRACT:

Background

The SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG) apheresis to control autoimmune disease activity is unknown. We aimed to examine the humoral immune response after mRNA-1273 Moderna^® vaccination in immunoapheresis patients.

Methods

We prospectively monitored SARS-CoV-2 IgG spike (S) protein antibody levels before and after each IgG (exposure) or lipid (LDL) apheresis (controls) over 12 weeks and once after 24 weeks. Primary outcome was the difference of change of SARS-CoV-2 IgG S antibody levels from vaccination until week 12, secondary outcome was the

SUBMITTER: Gaggl M 

PROVIDER: S-EPMC9549982 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature